Publications by authors named "Henrique D Teixeira"

Claim this Profile
E
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
Alan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, Eric L Simpson, Kim A Papp, Henrique D Teixeira

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years.
Christopher G Bunick, Alan D Irvine, Jonathan I Silverberg, Emma Guttman-Yassky, Mona Shahriari, Henrique D Teixeira

J Eur Acad Dermatol Venereol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.
Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, Kilian Eyerich, Norito Katoh, Henrique D Teixeira

Dermatol Ther (Heidelb)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
Amy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, Lawrence F Eichenfield, Weily Soong, Henrique D Teixeira

JAMA Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis.
Yuli Qian, Eliza M Raymundo, Shuai Hao, Kristina Unnebrink, Gweneth F Levy, Henrique D Teixeira

Clin Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®.
Jonathan I Silverberg, Marjolein de Bruin-Weller, Brian M Calimlim, Xiaofei Hu, Sarah A Ofori, Henrique D Teixeira

Dermatitis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Jonathan I Silverberg, Melinda J Gooderham, Amy S Paller, Mette Deleuran, Christopher G Bunick, Henrique D Teixeira

Am J Clin Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
Kilian Eyerich, Melinda J Gooderham, Juan Francisco Silvestre, Stephen P Shumack, Pedro Mendes-Bastos, Henrique D Teixeira

J Eur Acad Dermatol Venereol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
Emma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi, Kim A Papp, Sonja Ständer, Henrique D Teixeira

J Eur Acad Dermatol Venereol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis.
Mohamed Ismail, Eva Doelger, Doerthe Eckert, Alan D Irvine, Alvina D Chu, Henrique D Teixeira

Br J Clin Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.
Jonathan I Silverberg, H Chih-Ho Hong, Brian M Calimlim, Wan-Ju Lee, Henrique D Teixeira

Dermatol Ther (Heidelb)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, Vivian Laquer, Alison Fischer, Henrique D Teixeira

J Am Acad Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Amy S Paller, Barry Ladizinski, Pedro Mendes-Bastos, Elaine Siegfried, Weily Soong, Henrique D Teixeira

JAMA Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study.
Norito Katoh, Yukihiro Ohya, Hiroyuki Murota, Masanori Ikeda, Xiaofei Hu, Henrique D Teixeira

Dermatol Ther (Heidelb)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
Pedro Mendes-Bastos, Barry Ladizinski, Emma Guttman-Yassky, Ping Jiang, John Liu, Henrique D Teixeira

J Am Acad Dermatol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis.
Jonathan I Silverberg, H Chih-Ho Hong, Jacob P Thyssen, Brian M Calimlim, Avani Joshi, Henrique D Teixeira

Dermatol Ther (Heidelb)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.
Norito Katoh, Yukihiro Ohya, Hiroyuki Murota, Masanori Ikeda, Xiaofei Hu, Henrique D Teixeira

JAAD Int· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Andrew Blauvelt, Henrique D Teixeira, Eric L Simpson, Antonio Costanzo, Marjolein De Bruin-Weller

JAMA Dermatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Emma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, Kim A Papp, Aileen L Pangan

Lancet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Kristian Reich, Henrique D Teixeira, Marjolein de Bruin-Weller, Thomas Bieber, Weily Soong

Lancet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Mohamed-Eslam F Mohamed, Sathej Gopalakrishnan, Henrique D Teixeira, Ahmed A Othman

J Clin Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Emma Guttman-Yassky, Brett King, Henrique D Teixeira

J Am Acad Dermatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.
Errol P Prens, Aida M Lugo-Somolinos, Amy S Paller, Francisco Kerdel, Yinghui Duan, Henrique D Teixeira

Am J Clin Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2.
Mohan Liu, Jacob Degner, Robert W Georgantas, Ahmed Nader, Nael M Mostafa, Henrique D Teixeira

J Invest Dermatol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
Emma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, H Chih-Ho Hong, Kim A Papp, Henrique D Teixeira

J Allergy Clin Immunol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis